A Trial Called SCHOLAR and the Case for Not Stopping Yet
Every prior protocol for this exact finding says hold the drug. A newer, small trial asked what happens if you don't, treated the heart alongside the cancer instead, and the answer complicates what used to be a simple rule.
K.M., a 52-year-old woman, has worked as a dental hygienist for over twenty-five years and has continued seeing patients part-time throughout her treatment, something she says keeps her feeling like herself on the days chemotherapy doesn't. She was diagnosed with HER2-positive breast cancer eight months ago and has been on adjuvant trastuzumab following completion of chemotherapy, now four months into a planned twelve-month course. Her baseline echocardiogram before starting was normal, LVEF 62%, and her three-month surveillance echocardiogram was unchanged.
Her most recent surveillance echocardiogram, obtained today at the four-month mark, shows LVEF 47%, an absolute decline of 15 percentage points from baseline, asymptomatic throughout. Standard trastuzumab cardiotoxicity protocols, built into most clinical trial designs and widely adopted in practice, would call for holding the drug at this threshold — the conventional criterion is a fall of at least 10 percentage points to a value below the lower limit of normal (LLN), or a fall of 16 points or more from baseline whatever the absolute value; her 15-point drop to 47% meets the first of those. What complicates a reflexive hold is newer evidence testing a different approach directly: the SCHOLAR trial, a 20-patient phase I study enrolling patients with LVEF between 40% and the lower limit of normal, or a fall of 15 points or more, continued trastuzumab while starting ACE-inhibitor and beta-blocker cardioprotective therapy in a dedicated cardio-oncology clinic, rather than holding by default. Ninety percent of those patients received all their planned trastuzumab doses, and mean LVEF in that trial actually rose from 49% at enrollment to 55% at twelve months on cardioprotection — a genuinely different answer to the same threshold that standard protocols still treat as an automatic stop.
At the cardio-oncology review
The standard protocol at this threshold — a 15-point drop landing below the lower limit of normal — calls for holding trastuzumab, and interrupting a curative-intent HER2-targeted regimen has real oncologic cost. I don't want to hold reflexively if there's a genuine alternative.
There is one, and I want to name it directly rather than treat the standard hold criterion as the only option. SCHOLAR, a phase I trial, specifically tested continuing trastuzumab through this exact threshold range while starting ACE-inhibitor and beta-blocker therapy in a dedicated cardio-oncology setting — ninety percent of those patients completed their planned doses, and mean LVEF actually rose from 49% to 55% over the following year on cardioprotection. That's a small trial, not a guideline-level change yet, but it's a real, tested alternative to an automatic hold.
I'd want her monitored closely enough to catch the roughly one-in-ten outcome that trial also found — a subset who still progressed to real heart failure despite cardioprotection — so continuing isn't a decision we make once and then stop watching.
That's the balance I'd want too. Starting lisinopril and carvedilol today, continuing trastuzumab on schedule rather than holding, with echocardiograms every four to six weeks rather than the standard three-month interval given how recent and how large this specific decline was.
Lisinopril and low-dose carvedilol started. Trastuzumab continued on its existing schedule rather than held. Surveillance echocardiogram interval shortened to every 4-6 weeks given the recency and magnitude of the decline.
Explicitly framed as a monitored trial of an alternative approach, not a settled protocol change:
The continue-rather-than-hold approach will have worked for her specific case, consistent with the phase I trial's majority outcome.
Trastuzumab would be held at that point, consistent with the minority outcome the same trial also documented.